Pemvidutide vs Survodutide
The two GLP-1/glucagon dual agonists, both investigational, chasing different prizes: one is optimizing body composition, the other has already read out Phase 3.
Short answer
Both have human clinical data behind them, which makes the goal the real difference between pemvidutide and survodutide. For a reader focused on weight loss and MASLD/MASH, pemvidutide is the relevant choice; survodutide is marketed for weight loss and MASH. Both are legitimately available only inside clinical trials.
Pemvidutide
A GLP-1/glucagon dual agonist aimed specifically at preserving lean mass while cutting liver fat; real Phase 2 MASLD data, but Phase 3 has not started and it remains fully investigational.
Full Pemvidutide evidence reviewSurvodutide
A GLP-1/glucagon dual agonist in Phase 3 for both obesity and MASH; genuine placebo-controlled efficacy data in both indications, but no approval anywhere yet.
Full Survodutide evidence reviewPemvidutide vs Survodutide: head to head
- FDA status / approved use
Pemvidutide
Investigational, not approved anywhere; Phase 2b complete, FDA Breakthrough Therapy Designation for MASH, Phase 3 plannedSurvodutide
Investigational; positive Phase 3 obesity and liver trials, not yet approved anywhere- Marketed for
Pemvidutide
Weight loss, MASLD/MASHSurvodutide
Weight loss, MASH- Outcome areas
Pemvidutide
Weight loss / appetite; Liver / detox; Muscle / strength / lean massSurvodutide
Weight loss / appetite; Liver / detox- Evidence grade
Pemvidutide
Clinical dataSurvodutide
Clinical data- How it works
Pemvidutide
Dual GLP-1 and glucagon receptor agonist; glucagon arm stimulates liver fat oxidationSurvodutide
Activates GLP-1 and glucagon receptors to curb appetite and raise energy expenditure- Route and dosing
Pemvidutide
Once-weekly injectionSurvodutide
Subcutaneous injection, once weekly- Headline human result
Pemvidutide
About −15.6% mean weight loss at 2.4 mg vs −2.2% on placebo over 48 weeks in the Phase 2 MOMENTUM trial (391 adults)Survodutide
Mean weight change about −16.6% vs −3.2% on placebo at 76 weeks in the 2026 Phase 3 SYNCHRONIZE-1 trial- Strongest evidence
Pemvidutide
Phase 2 MASLD RCT, 2025Pemvidutide evidence reviewPubMed 41237796Survodutide
Phase 2 obesity RCT, 2024Survodutide evidence reviewPubMed 38330987- Key safety signal
Pemvidutide
No long-term safety data; glucagon action needs long-term cardiometabolic monitoringSurvodutide
Common, dose-related nausea, diarrhea and vomiting- How it is obtained
Pemvidutide
Legitimately available only inside clinical trials; vials sold online are gray-market research chemicalsSurvodutide
Legitimately available only inside clinical trials; vials sold online are gray-market research chemicals
| Pemvidutide | Survodutide | |
|---|---|---|
| FDA status / approved use | Investigational, not approved anywhere; Phase 2b complete, FDA Breakthrough Therapy Designation for MASH, Phase 3 planned | Investigational; positive Phase 3 obesity and liver trials, not yet approved anywhere |
| Marketed for | Weight loss, MASLD/MASH | Weight loss, MASH |
| Outcome areas | Weight loss / appetite; Liver / detox; Muscle / strength / lean mass | Weight loss / appetite; Liver / detox |
| Evidence grade | Clinical data | Clinical data |
| How it works | Dual GLP-1 and glucagon receptor agonist; glucagon arm stimulates liver fat oxidation | Activates GLP-1 and glucagon receptors to curb appetite and raise energy expenditure |
| Route and dosing | Once-weekly injection | Subcutaneous injection, once weekly |
| Headline human result | About −15.6% mean weight loss at 2.4 mg vs −2.2% on placebo over 48 weeks in the Phase 2 MOMENTUM trial (391 adults) | Mean weight change about −16.6% vs −3.2% on placebo at 76 weeks in the 2026 Phase 3 SYNCHRONIZE-1 trial |
| Strongest evidence | Phase 2 MASLD RCT, 2025Pemvidutide evidence reviewPubMed 41237796 | Phase 2 obesity RCT, 2024Survodutide evidence reviewPubMed 38330987 |
| Key safety signal | No long-term safety data; glucagon action needs long-term cardiometabolic monitoring | Common, dose-related nausea, diarrhea and vomiting |
| How it is obtained | Legitimately available only inside clinical trials; vials sold online are gray-market research chemicals | Legitimately available only inside clinical trials; vials sold online are gray-market research chemicals |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Survodutide is further along by a wide margin. Its Phase 3 SYNCHRONIZE-1 (n=725, 76 weeks) reported about −16.6% mean weight loss against −3.2% on placebo, and SYNCHRONIZE-MASLD (n=216) reported 84.2% of participants achieving at least a 30% reduction in liver fat with 61.0% normalizing it. Pemvidutide is still Phase 2: MOMENTUM (391 adults, 48 weeks) produced about −15.6% at 2.4 mg versus −2.2% on placebo, and its IMPACT Phase 2b trial met MASH resolution without worsening fibrosis at 24 weeks. Pemvidutide’s distinguishing claim is body composition — Altimmune reported roughly 74.5% of the weight lost was fat and 25.5% lean — but that is a company-reported ratio framed around the hypothesis the program was designed to test, not a finding another trial has confirmed, and it should not be read as an established advantage. Neither drug is approved anywhere.
Pemvidutide fits if
You care specifically about the lean-mass-preservation hypothesis and want to watch whether it survives a Phase 3 that has not started yet.
Survodutide fits if
You want the dual agonist with real Phase 3 data in both obesity and liver disease — the one likelier to reach a regulator first.
Pemvidutide vs Survodutide: common questions
- Is either pemvidutide or survodutide FDA-approved?
- No. Pemvidutide is investigational, not approved anywhere; Phase 2b complete, FDA Breakthrough Therapy Designation for MASH, Phase 3 planned. Survodutide is investigational; positive Phase 3 obesity and liver trials, not yet approved anywhere.
- Which has stronger human evidence, pemvidutide or survodutide?
- Neither clearly. Both have human clinical data. The key source for pemvidutide is phase 2 MASLD RCT, 2025; for survodutide, it is phase 2 obesity RCT, 2024.
- What are the main safety concerns with pemvidutide and survodutide?
- Pemvidutide has no long-term safety data; glucagon action needs long-term cardiometabolic monitoring. For survodutide, watch for common, dose-related nausea, diarrhea and vomiting.
Key studies behind each
Pemvidutide
- Harrison SA, Browne SK, Suschak JJ, et al. (2025). Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. PubMed 39002641
- Noureddin M, Harrison SA, Loomba R, et al. (2025). Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. PubMed 41237796
Survodutide
- le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. PubMed 38330987
- Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, et al. (2024). A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. PubMed 38847460
The full evidence reviews
- Pemvidutide: the GLP-1/glucagon dual agonist betting on lean-mass preservation
Altimmune's investigational dual agonist isn't chasing the biggest weight-loss number — it's chasing better body composition and liver benefit. A straight read of the Phase 2 evidence.
Updated August 2026
- Survodutide (BI 456906): the GLP-1 / glucagon dual agonist and its Phase 2 and Phase 3 data
An investigational dual agonist that adds glucagon to GLP-1 — with Phase 2 signals now confirmed in published Phase 3 trials: about 16.6% weight loss and strong liver-fat results. A straight read of the evidence and its limits.
Updated August 2026